Cara Banks $15M for Pursuit of Nonaddictive Pain Drug, by Donna Young (BioWorld Today) The $15 million Series D financing Cara Therapeutics Inc. closed this week will go a long way toward advancing the development of its peripherally restricted kappa opioid agonist CR845, said CEO Derek Chalmers...
Cara's No-Brainer Opioid Solution San Carlos, CA, Feb 22, 2010 /The Bernstein Report on BioBusiness/ — Cara Therapeutics, Inc. believes its CR845 kappa opioid agonist will fare better than others because the peptide is too large to cross the blood-brain barrier, meaning it should avoid the side
Cara Therapeutics Reports Positive Phase II Data for Novel Peripheral Analgesic In Acute Post-Operative Pain Shelton, CT, Feb 8, 2010 /PRNewswire-FirstCall/ — Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa
Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic In Acute Post-Operative Pain Shelton, CT, Jan 12, 2009 /PRNewswire-FirstCall/ — Cara Therapeutics, Inc. today announced that it is initiating a Phase II clinical trial of its long-acting peripheral kappa opioid agonist,
Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845 Cara Therapeutics, Inc. today announced completion of a Phase I clinical trial for its second-generation, peripherally acting kappa opioid agonist, CR845, under development for the treatment of
Cara Therapeutics Secures $12.3 Million In Series C Extension Financing Cara Therapeutics, Inc. announced today that it had closed on $12.3 million of additional funding to its original $24 million Series C financing which was completed in 2007. The round was led by new investor, Devon Park